Skip to content
Shredy
  • Features
  • How it works
Talk to Experts
    1. R&D leaderboard
    2. /
    3. Eupraxia Pharmaceuticals

    Eupraxia Pharmaceuticals R&D spend

    Eupraxia Pharmaceuticals Inc. · EPRX (TSX) · Victoria, BC · Pharmaceuticals

    Latest R&D (CAD)
    $29.8M
    Period ended 2025-12-31
    Revenue (CAD)
    —
    — of revenue
    Filings in database
    4
    Investor relations →

    R&D by fiscal period

    2025
    $29.8M
    2024
    $22.0M
    2023
    $27.5M
    2022
    $17.7M
    Period endR&D (CAD)Revenue (CAD)Native R&DFormSource
    2025-12-31$29,817,389—$21,331,656 USD40-FSEC EDGAR
    2024-12-31$22,025,392—$16,079,276 USD40-FSEC EDGAR
    2023-12-31$27,484,108—$20,363,124 USD40-FSEC EDGAR
    2022-12-31$17,736,529—$13,629,854 USD40-FSEC EDGAR
    Shredy

    A clearer path from your R&D work to a well-prepared SR&ED claim.

    Built in Vancouver. For Canadian innovators.

    Shredy

    • Features
    • How it works
    • Talk to Experts
    • About us

    Resources

    • FAQ
    • Blog
    • Find a consultant
    • Research funding
    • Startup funding
    • Innovation grants

    Free tools

    • SR&ED eligibility quiz
    • T661 checklist
    • Grant finder
    • R&D leaderboard
    • R&D credit calculator
    • Explore all tools

    SR&ED across Canada

    • Ontario
    • British Columbia
    • Alberta
    • Quebec
    • Saskatchewan
    • Manitoba
    • Toronto
    • Vancouver
    • Calgary
    • Montreal
    • Ottawa
    • Edmonton

    © 2026 Shredy. All rights reserved.

    Privacy policyTerms of service